Structure-based drug design (SBDD) is an iterative approach to the discovery of
potential new drugs. It depends on extensive interaction and collaboration
among molecular and structural biologists, synthetic and theoretical
chemists. Many of the research projects at the UW Biomolecular Structure
Center use this approach to target specific diseases, particularly those
caused by tropical parasites.
The SGPP consortium is one of 9 Structural Genomics funded by the NIH to
develop new technologies for high-throughput protein expression and
structure determination. The specific targets of the SGPP effort are
proteins from the disease-causing organisms
Leishmania major, Trypanosoma brucei, Trypanosoma cruzi
and Plasmodium falciparum.